Five companies faced unexpected shifts in their financing plans mid-engagement. The takeaway for Philadelphia: capital strategy can’t be treated as a discrete fundraising exercise. It needs to be built into how companies operate.
This year, we worked closely with seven promising Capital Readiness (CRP) alumni made up of health and medtech companies to figure out where the gaps were in progressing from innovation to commercialization. Across the first cohort, they were not always successful for a reason no founder controls: the money moved away.
None of these companies stalled because the science failed. A thoracic surgical device had FDA clearance and strong first-in-human results. A spine implant company was commercial-stage with an encouraging early fusion signal. A wearable respiratory diagnostic company had matched the imaging gold standard. Yet in all five cases, a financing round shifted under the company's feet during our 60–90 day engagement window.
What We Saw
A clear pattern of capital complications emerged beyond the companies' control. When its expected equity financing faltered, the spine implant company opened a convertible bridge to preserve runway. The wearable respiratory diagnostic company opted for bridge financing at a steep discount to its next round, with a pharma partnership decision hanging over its valuation.
For a maternal digital health company, a strategic partner's planned equity check fell through after the partner's own compliance review flagged a conflict. Growth investors were circling, but only if the company hit a specific revenue threshold by year end. Meanwhile, a cardiac medical-device spinout funded itself entirely with grants and was pursuing a federal award large enough to reshape its future, but an FDA review delay held up its lead investor's timeline.
None of this reflected company performance. Lead investors delayed or under-raised their own funds. Regulator reviews took longer than expected. The company's in-house and external compliance teams intervened. Good companies were forced into defensive financing by conditions entirely outside their control.
What Worked
The interventions that changed outcomes were operational, not abstract.
- Rebuilding and reshaping the round. When the thoracic surgical device company's commitment collapsed, the Science Center opened new investor introductions and helped recraft the near-term raise around a smaller equity ask matched to anticipated state grant funding.
- Restructuring rather than abandoning. When a planned equity investment was blocked by a compliance conflict, the maternal digital health company secured a non-dilutive loan from the prospective partner and a convertible note from existing investors.
- Leading complex funding operations. For the cardiac medical device company, the Science Center led a major federal application, ran weekly planning calls, and supported congressional and agency engagement. For a clinical stress-biomarker company, we served as the credentialed nonprofit administrative partner a large international mental-health award required.
- Messaging the delay. Coaching a founder on how to explain a regulatory slip to a prospective lead investor kept a viable follow-on investor engaged and confident in the process.
How Philadelphia Can Respond
For founders: Treat bridge structures, scenario plans, and non-dilutive capital as standing infrastructure, not emergency measures. Build two or three financing paths before you need any of them.
For regional investors and family offices: Signal early and plainly when your own fund timing is shifting. A late withdrawal costs a company months; an early one only costs it weeks. Engaging through the Capital Readiness Program and our investor network gives you an early, structured view of companies before their rounds are under pressure.
For grant makers and public funders: Large federal and state awards increasingly require a qualified nonprofit partner. The Science Center can serve that role, turning otherwise inaccessible funding into a live possibility for seed-stage companies.
How the Science Center responds: Build investment and grant-partner processes that can act within a round's timeline, and use structured quarterly check-ins to track whether financing scenarios are advancing toward closing.
Capital Strategy Can't be an Afterthought
Capital timing is a market condition, not a company failing. A company can avoid translation failure by seeking outside guidance that can help them navigate and adapt to unexpected delays. The Science Center's role is to be there when the round moves, so the path to patients does not move with it.
Where Good Companies Get Stuck: Field Notes on the Commercialization Gap
This is the first of five articles drawn from 90 days of embedded work with seven health and medtech companies. This series highlights the patterns that emerged, determining whether a breakthrough reaches patients.